Biotech News

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Jaguar Health (JAGX)jaguarhealth.gcs-web.com2026-06-12 13:07 ESTConference / presentation

Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

JAGXJaguar Health2026-06-08 16:16:01 EST

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

JAGXJaguar Health2026-05-28 18:17:38 EST

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

JAGXJaguar Health2026-05-27 17:13:23 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGXJaguar Health2026-05-21 00:47:24 EST

Jaguar Health Reports First Quarter 2026 Financials

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Specialty Pharmaceuticals
Location: San Francisco, California